Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
A Phase 3 multiple myeloma research setting reflects Johnson & Johnson’s MonumenTAL-6 study, in which the Tecvayli-Talvey combination reportedly reduced the risk of disease progression or death by 89%. Representative image.
Pharma & Biotech

MonumenTAL-6 trial strengthens Johnson & Johnson’s dual-target multiple myeloma strategy

Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.

Read More
A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.
Pharma & Biotech

argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology

argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.

Read More
Bio-Thera Solutions has begun Phase 1 testing of BAT8013, an investigational CD25-targeting antibody-drug conjugate being evaluated in patients with advanced solid tumors. Representative image.
Pharma & Biotech

Can Bio-Thera’s BAT8013 turn regulatory T-cell depletion into a workable solid-tumor strategy?

Bio-Thera has dosed the first patient in BAT8013’s Phase 1 trial. See why safety, Treg selectivity and dose choice will decide its future.

Read More
Synaptiq Therapeutics is advancing the acquired SYN-001 clinical programme toward a Phase IIb trial targeting neuropsychiatric symptoms associated with 22q11.2 deletion syndrome. Representative image.
Pharma & Biotech

What Synaptiq Therapeutics’ SYN-001 acquisition means for 22q11.2 deletion syndrome

Synaptiq Therapeutics acquires SYN-001 and plans a Phase IIb trial for neuropsychiatric symptoms in 22q11.2 deletion syndrome.

Read More
AnHorn Medicines has begun first-in-human testing of AH-008 as the biotechnology company investigates whether the experimental therapy could help prevent chemotherapy-induced peripheral neuropathy. Representative image.
Pharma & Biotech

AnHorn Medicines doses first participant in Phase 1 AH-008 CIPN prevention trial

AnHorn Medicines doses the first participant in a Phase 1 AH-008 study, opening a cautious clinical test of chemotherapy neuropathy prevention.

Read More
Novellia’s GLP-1 and Metabolic Health Registry aims to track weight outcomes, treatment persistence and coverage disruptions across complex patient journeys, addressing evidence gaps left by traditional healthcare datasets. Representative image.
Pharma & Biotech

Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?

See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.

Read More
AcroCyte Therapeutics is advancing scalable human kidney organoid research through its ARPA-H-funded RACE programme, targeting new manufacturing capabilities for regenerative medicine and bioartificial kidney development. Representative image.
Pharma & Biotech

Can AcroCyte turn a $4.3m ARPA-H award into a scalable bioartificial kidney platform?

AcroCyte’s $4.3m ARPA-H-backed RACE project targets scalable autologous kidney organoids, but manufacturing and animal data remain the key tests.

Read More
Laboratory research into AbelZeta Pharma’s C-CAR031 armored GPC3 CAR-T therapy highlights the emerging potential and durability challenges of cellular treatment for advanced hepatocellular carcinoma. Representative image.
Pharma & Biotech

AbelZeta and AstraZeneca study identifies GPC3 loss as a potential C-CAR031 resistance mechanism

AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.

Read More
Representative image: A retina specialist reviews advanced eye scans as Roche’s $RHHBY Susvimo moves closer to European approval, offering wet age-related macular degeneration patients a refillable implant designed to reduce frequent eye injections.
Pharma & Biotech

Roche gains positive CHMP opinion for Susvimo in wet age-related macular degeneration

Roche’s Susvimo wins a positive European opinion for wet AMD. See how two yearly refills could reduce injections and reshape retinal care.

Read More
Apertura Gene Therapy’s TfR1 CapX delivery platform will support an ARPA-H-backed consortium developing gene-editing therapies for Dravet syndrome, alternating hemiplegia of childhood and other rare pediatric neurological diseases. Representative image.
Pharma & Biotech

Apertura joins $34.5m ARPA-H PERC program for rare pediatric CNS gene editing

Apertura joins Broad’s $34.5 million ARPA-H PERC program, pairing TfR1 CapX with gene editing for rare pediatric brain diseases.

Read More